| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.44 | 3e-46 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-14 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.23 | 9e-14 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.21 | 1e-12 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-12 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.22 | 4e-12 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.18 | 5e-09 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.28 | 7e-09 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.27 | 6e-08 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-07 |